Sunshine Biopharma Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Sunshine Biopharma Inc. now
Current reporting with the operating signal separated from the noise.
Sunshine Biopharma Inc.: Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
Sunshine Biopharma Inc.: Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer
The story matters when it changes Sunshine Biopharma Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest SBFM filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
10-QQuarterly financial reportFiled 2026-08-13 · Period 2026-06-30SEC ↗10-QQuarterly financial reportFiled 2026-05-13 · Period 2026-03-31SEC ↗10-KAnnual financial reportFiled 2026-04-03 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-09-16 · Period 2026-09-15SEC ↗8-KMaterial company eventFiled 2026-09-11 · Period 2026-09-11SEC ↗8-KMaterial company eventFiled 2026-08-28 · Period 2026-08-25SEC ↗DEF 14AProxy and shareholder meetingFiled 2025-10-23 · Period 2025-12-11SEC ↗PRE 14COfficial SEC filingFiled 2026-09-16 · Period 2026-09-15SEC ↗
Sunshine Biopharma Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →